v3.24.2
Intangible Assets
 6 Months Ended
Jun. 30, 2024
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Intangible Assets
6. Intangible Assets
The following table presents details of the Company’s acquired intangible assets as of June 30, 2024 and December 31, 2023 (in thousands, except weighted-average amortization period):
As of June 30, 2024Weighted-Average Amortization PeriodGross Carrying AmountAccumulated AmortizationNet
Finite-lived intangible assets:
Developed technology1
8.8 years$83,289 $(83,289)$— 
Customer relationships15.0 years6,388 (2,981)3,407 
Trade secrets and processes20.0 years5,256 (1,708)3,548 
Total intangible assets 17.6 years$94,933 $(87,978)$6,955 
1During the three months ended June 30, 2024, the Company recorded an impairment of developed technology charge of $58.9 million included within accumulated amortization in the table above. Refer to Note “4. Impairment of Immersive Healthcare Asset Group” for more details.
As of December 31, 2023Weighted-Average
Amortization Period		Gross Carrying AmountAccumulated AmortizationNet
Finite-lived intangible assets:
Developed technology8.8 years$83,289 $(19,640)$63,649 
Customer relationships15.0 years6,579 (2,851)3,728 
Trade secrets and processes20.0 years5,256 (1,577)3,679 
Total intangible assets9.6 years$95,124 $(24,068)$71,056 
The gross carrying amount and accumulated amortization of the customer relationships are the only intangible assets subject to foreign currency translation effects. The Company’s $5.3 million trade secrets and processes intangible asset was recognized in connection with a royalty buyout agreement in 2018.
The following table presents the amortization recorded related to the Company’s finite-lived intangible assets for the three and six months ended June 30, 2024 and 2023 (in thousands):
 Three Months Ended June 30,Six Months Ended June 30,
 2024202320242023
Cost of revenue$66 $66 $131 $131 
Sales, general and administrative1
2,486 2,488 4,974 4,975 
Total$2,552 $2,554 $5,105 $5,106 
1This does not include the impairment charge of $58.9 million related to the Company’s immersive healthcare developed technology during the three months ended June 30, 2024. Refer to Note “4. Impairment of Immersive Healthcare Asset Group” for more information.